ALPS Advisors’s Heron Therapeutics HRTX Stock Holding History

ALPS Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-115,864	Closed	-$1.72M	–	858
2020 Q3	$1.72M	Sell	115,864 -7,788	-6%	-$122K	0.03%	253
2020 Q2	$1.82M	Buy	+123,652	New	+$2.03M	0.02%	247
2018 Q4	–	Sell	-137,559	Closed	-$4.35M	–	903
2018 Q3	$4.35M	Buy	137,559 +33,836	+33%	+$1.26M	0.03%	175
2018 Q2	$4.03M	Buy	103,723 +17,646	+21%	+$562K	0.03%	185
2018 Q1	$2.38M	Buy	86,077 +25,679	+43%	+$583K	0.02%	198
2017 Q4	$1.09M	Buy	+60,398	New	+$985K	0.01%	247

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ALPS Advisors's HRTX Position: Q4 2020 in Review

ALPS Advisors sold out of Heron Therapeutics (HRTX) in Q4 2020, closing a stake of 115,864 shares — an estimated $1.72M sold.

ALPS Advisors first reported a position in HRTX in Q4 2017 and held it in 6 quarters. The position peaked at $4.35M in Q3 2018. 189 funds tracked by Wall St. Rank hold HRTX as of Q4 2020.

ALPS Advisors reported no remaining Heron Therapeutics position as of Q4 2020 after selling out during the quarter.
ALPS Advisors sold 115,864 Heron Therapeutics shares in Q4 2020, an estimated $1.72M.
ALPS Advisors first reported a position in Heron Therapeutics in Q4 2017 and held it in 6 quarters.
ALPS Advisors's Heron Therapeutics position peaked at $4.35M in Q3 2018.
189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2020.

Based on ALPS Advisors's 13F filing for Q4 2020, filed 3 Feb 2021.